Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 3,401–3,500 of 3,704
Hajj‐Boutros, G., & Morais, J. A. (2026) · Springer eBooks · doi:10.1007/978-3-032-26761-0_14
Palka, W., Moćko, P., Śladowska, K., Holko, P., & Kawalec, P. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03006-y
Real‐World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort
Rosenior-Patten, O., Lees, Z., Rowe, R., Hussain, S., Ahmad, E., Brooke, E., Dix, S., & Maybury, C. M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71067 · Cited by 3
Lim, S. K., Hwang, Y., Son, J. W., Lee, S., Jung, C. H., Kim, H., Lim, H., Park, S., Kim, J., Youn, J., et al. (2026) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2026.6.e26
Rey, S. B., González, G. A., de la Plaza, I. R., Prieto, A. S., Lamelas, A. F., & Valenzuela, E. F. (2026) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2026.502837
GLP-1-based multipharmacology: Biased signaling as a determinant of therapeutic efficacy
Li, W., Yan, J., Zhao, F., & Yang, D. (2026) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2026.07.001
Choi, L. Y., Kim, M. H., Jin, S. C., & Yang, W. M. (2026) · Innovations in Acupuncture and Medicine · doi:10.1186/s44424-026-00066-y
Zhou, S., & Dong, L. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108369
Metabolic Determinants of Weight-Loss Quality During and After Incretin-Based Therapies in Obesity
Luna, M., Rodrigues, B., & Ramalho, A. (2026) · Clinical Nutrition Open Science · doi:10.1016/j.nutos.2026.100711
Retatrutide: prospects and potential risks in oncology and ophthalmology
Kenkishvili, A. S., Arutyunyan, M. E., & Maksimov, М. L. (2026) · Spravočnik vrača obŝej praktiki (Journal of Family Medicine) · doi:10.33920/med-10-2607-03
Microdosing Tirzepatide in Multi‐Dose Pens: Clinical Individualization, Safety, and Evidence Gaps
Lara, F. V.-O. D. (2026) · Obesity · doi:10.1002/oby.70282
Trends in preoperative weight loss modalities among patients receiving body contouring surgery
Liang, J., Anderson, J. L., Cathey, J. M., Zhang, J., Yi, V. N., & Patel, A. (2026) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2026.08.008 · Cited by 1
Hasoon, J. J., Nguyen, A., Viswanath, O., Urits, I., & Robinson, C. L. (2026) · Current Pain and Headache Reports · doi:10.1007/s11916-026-01546-9
Hsu, H.-C., Shih, L., Hou, Y., & Lu, K. (2026) · Biomolecules · doi:10.3390/biom16081155
Vignera, S. L., & Condorelli, R. A. (2026) · Medicina · doi:10.3390/medicina62081536
Gómez-Maldonado, I., Rodríguez-Arana, A., Tamayo-Pinzón, A., Albornoz-Suárez, J. E., Lopez-Franco, M. J., Mejia-Manrique, J. A., Forero-Caycedo, J. J., Rojas-Rodríguez, L. C., Buitrago-Ricaurte, N., Gaviria-Carrillo, M., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167108
ПЛЕЙОТРОПНЫЕ ЭФФЕКТЫ АГОНИСТОВ РЕЦЕПТОРОВ ГЛЮКАГОНОПОДОБНОГО ПЕПТИДА‑1
Юрьевич, Ц. В., Lazareva, I. A., Владимировна, Б. Н., Полякова, О. В., & Николаевна, У. С. (2026) · Современные проблемы науки и образования · doi:10.17513/spno.34690
Piguet, C. E. M., Nucci, R., & Beaudry, J. L. (2026) · The Journal of Physiology · doi:10.1113/jp291081 · Cited by 1
Talay, L., Xu, C., Alderete, J., Hom, J., Tan, M., & Ahuja, N. (2026) · Diabetes, obesity and metabolism · doi:10.1111/dom.71181
Sattar, N. A., Mamas, M. A., Li, R., García‐Pérez, L., Chen, K. L., Upadhyay, N., Glass, L., Batterham, R. L., Dimitriadis, G. K., & Liu‐Seifert, H. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag408
Hunter, T. M., Venkataraman, M., Mojdami, D., Vallarino, C. R., Stockbower, G. E., Grabner, M., Ananth, M., & Desai, K. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71064 · Cited by 1
Raptis, D., Nazarenko, N., Agarwal, R., Shah, M. K., Gao, Y., Theodoropoulos, P., Borkowski, P., Maliha, M., Policarpio, M. A., Yakkali, S., et al. (2026) · Diabetology · doi:10.3390/diabetology7080155
Alves, M. L. M., Costa, A. O. D. S. M., Costa, J. D. V. M., Garrido, G. A., Gonzalez, J. V. P., Ferreira, J. S. N., & Pereira, B. D. A. (2026) · North American Spine Society Journal (NASSJ) · doi:10.1016/j.xnsj.2026.100938
Dallal, R. M., Lam, P., & Das, A. (2026) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2026.08.013 · Cited by 1
Valdez, Y., Segev, N., Parimi, N., Vegesna, M., Brown, E. A., Samuels, S. L., Name, M. A. V., SHAH, A. S., & Wolf, R. M. (2026) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2026-0335
Jiang, C., Qiu, J., Wei, C., Zhou, E., Zhu, H., Huang, W., Zhou, T., & Hu, J. (2026) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70180
Thombre, K. R., Gupta, K. R., & Umekar, M. J. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100739
Guglielmi, V., Musumeci, G., Galeone, C., Mariani, P., Baratta, R., Bellini, R., Cameli, M., Castaldini, N., Cesaro, A., Cosentino, N., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03010-2
Digestive hormones and their impact on bariatric and pharmacologic weight-loss therapies
Amoyel, M., Carette, C., Poghosyan, T., Beyec, J. L., & Gall, M. L. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag032
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo
Yaseen, M., Ameer, A., Ali, Z., Jamali, J. A., Kumar, A., Siddiqui, M. B. A., Kumari, P., Hassaan, M., Nanwani, P., Basit, M. A., et al. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000005353
Dedanishvili, N. S., Pyurveev, S. S., Brus, T. V., & Vasiliev, A. G. (2026) · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук · doi:10.29413/abs.2026-11.3.20
Alhazmi, A. M., Alayoubi, F., Mufti, R. E., & Albulushi, A. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103423
Sasankan, D., & Mohan, R. (2026) · Cell Biochemistry and Function · doi:10.1002/cbf.70283
Ahmed, Z., Mustafa, N., Sarkar, T., & Yasmin, H. (2026) · Health Science Reports · doi:10.1002/hsr2.73044
Balasubaramaniam, V., Scobie, M., O’Kane, M. P. M., Graham, Y., Robertson, A. G., & Mahawar, K. K. (2026) · Nutrients · doi:10.3390/nu18162643
The Value of Adding Obesity Medications After Bariatric Surgery
Shaikh, S., & le Roux, C. W. (2026) · Current Surgery Reports · doi:10.1007/s40137-026-00530-x
Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review
Abdalla, S. A. M., Gharbawi, L., Elshaikh, N., Omer, E. O. E., Osman, A. F. M., Ali, A. S. H., Mohamed, T. M. Y., & Alhajri, A. H. M. (2026) · Cureus · doi:10.7759/cureus.114454
Yuan, R., Lan, Y., Wu, M., & Lu, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1857147 · Cited by 1
Sattar, N. A., Srinath, R., García‐Pérez, L., Lee, C. J., Karanikas, C. A., Chen, X., & Plat, A. W. (2026) · PLoS ONE · doi:10.1371/journal.pone.0345032
Xie, Y., Zhang, X., & Chen, B. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1913929
Wolfe, E. L., Bartl, L., Burks, H. R., Craig, L. B., Peck, J. D., & Hansen, K. R. (2026) · F&S Reports · doi:10.1016/j.xfre.2026.06.002
Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity
Mollero, E. L. M., Dozzani, I., Biamonte, E., Bendotti, G., Marzullo, P., Aimaretti, G., & Gallo, M. (2026) · Nutrients · doi:10.3390/nu18162654 · Cited by 3
Canecki-Varžić, S., Bilić-Čurčić, I., Bakula, M., Bulum, T., Naglić, M. Č., Delić-Brkljačić, D., Wensveen, T. T., Vitković, D. F., Jurišić‐Eržen, D., Klobučar, S., et al. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1834323 · Cited by 1
Impact of GAD-65 antibody detection on antihyperglycemic therapy in T2D
Halliburton, S., Herber, E., Pantalone, K. M., Parker, M., & Soric, A. (2026) · Endocrine Connections · doi:10.1530/ec-25-0785
For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Giang, C., Meng, J., Mohammad, M. A., Liu, Z., Wu, X., & Zhu, Y. (2026) · Biology · doi:10.3390/biology15161395 · Cited by 1
Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis
Chen, Q.-X., Xiao-yu, Z., Wu, Q., Xie, J.-J., Xu, Y., Teng, F., & Guo, M. (2026) · Endocrine · doi:10.1007/s12020-026-04757-7 · Cited by 1
Falahee, B. E., Ostrominski, J. W., Wagholikar, K. B., Ünlü, O., Zelle, D., Kumar, S., Gabovitch, D., Tucci, M. R., Smith, A., Nichols, H., et al. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70176
Elkin, J., Schilling, C. G., Thuraisingam, S., Hi, M. W., Sumithran, P., Choong, P., Dowsey, M. M., & Shadbolt, C. (2026) · The Medical Journal of Australia · doi:10.5694/mja2.70253
Grewal, U. S., Ear, P. H., Sonbol, M. B., Bellizzi, A. M., Hofland, J., Crona, J., Dillon, J. S., Chan, J. A., Howe, J. R., Strosberg, J., et al. (2026) · Cancer · doi:10.1002/cncr.70586
Kehar, M., Ramji, A. S., Swain, M., Singer, A. G., IVERS, N., Schaufert, W., Betel, M., Dasgupta, K., Sebastiani, G., & Patel, K. (2026) · Canadian Liver Journal · doi:10.3138/canlivj-2026-9-3-guidelines
Incretins beyond weight and hyperglycemia management: a consensus statement by AASD
Shaltout, I., Hegazy, M., Meligi, A. A. H. E., Abdelghaffar, S., Wifi, M.-N. A., Saleh, A. A., Hammad, H., Abouzeid, A. A. E. K., Fahmy, E. M., Maghraby, G. G., et al. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00689-w
The GLP ‐1–Mitochondria Axis in Metabolic Aging
Chang, R., Tsai, A. P., Wang, B., & Li, C.-J. (2026) · Aging Cell · doi:10.1111/acel.70676 · Cited by 1
Mazzone, P. M., Giacoppo, D., Ammirabile, N., Mauro, M. S., Spagna, F., & Capodanno, D. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag430
He, W., Yi-di, S., Wang, X., He, S.-Y., Tao, X., Yuan, S.-X., Zhou, L., & Long, E.-W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1889594
The adipose organ–capacitor model of preclinical and clinical obesity
Nisoli, E. (2026) · Trends Open · doi:10.1016/j.treopn.2026.07.013
Cho, D. (2026) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2026.6.e30
Ashtary‐Larky, D. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00751-2
Keyserling, T. C., Wu, Q., Ammerman, A. S., Berkowitz, S. A., Buse, J. B., Couper, D. J., Evenson, K. R., Hursting, S., Sotres‐Alvarez, D., Lyons, K. M., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.29006 · Cited by 1
Obesity, lipids, inflammation, and healthy aging
Rikhi, R. R., & Shapiro, M. D. (2026) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2026.08.006
Reappraising obesity management in the GLP-1 receptor agonist era
Christmas, T., Ahmed, A. R., & Tan, T. (2026) · npj Metabolic Health and Disease · doi:10.1038/s44324-026-00126-0
Wolszczak, A., Martynowska, W., Hajt, M., Misiaszek, D., Graczyk, A., Ciecierski, P., Grabowska, N., Motor, J., & Turzyńska, P. P. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.5940
Wada, N., Harada, N., Ikeguchi, E., Kiyobayashi, S., Hatoko, T., Seno, Y., Kurihara, T., Kaido, Y., Yamamoto, K., Yasuda, T., et al. (2026) · Journal of Molecular Endocrinology · doi:10.1530/jme-26-0016
Dhali, A., Biswas, J., Khan, F., Dahiya, D. S., & Mandal, S. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16080437
Falcão, L., Oliveira, L. D. B., Magalhães, P. L. M., Goyal, A., Maximiano, M. L. D. B., Donato, K. O., Silva, R. A. S., Gonzalez, J. V. P., da Silva, A. M. P., Corin, A. S., et al. (2026) · Headache The Journal of Head and Face Pain · doi:10.1111/head.70131 · Cited by 1
Strosahl, J. N., Ziegler, T. R., & Singh, R. H. (2026) · Nutrients · doi:10.3390/nu18162722
Weekly Journal Scan: SURMOUNT and MAINTAIN the summit: tirzepatide after successful bodyweight loss
Liuzzo, G., & Patrono, C. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag621
Boateng, S., Zahrawi, F., Ameyaw, P. A., Zai, M. J., Khosousi, M., Khungar, V., & Banini, B. A. (2026) · Livers · doi:10.3390/livers6040081
Hsia, S. H., Bays, H. E., Billings, L. K., Weideman, A. M., Mather, K. J., Coşkun, T., Haupt, A., Thomas, M. K., Tham, L. S., Calderón, B., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00160-9 · Cited by 1
Schifano, F., Luca, M. A. D., Bonaccorso, S., Arillotta, D., Floresta, G., Martinotti, G., Papanti, G. D., Corkery, J., Chiappini, S., & Guirguis, A. (2026) · Current Psychiatry Reports · doi:10.1007/s11920-026-01709-w · Cited by 1
Wangari‐Olivero, J., Paturi, J., Moreau, M., Qian, K., Stevenson, S., Yaxian, Z., & Zheng, Q. (2026) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.71145 · Cited by 1
Vignera, S. L., & Condorelli, R. A. (2026) · Pharmaceuticals · doi:10.3390/ph19081321
Temporal Changes in Mesorectal Fat Area After Bariatric Surgery: A Retrospective Cohort Study
Hijji, T. M., Wang, A., Abu‐Nada, M., Shammari, A. A., Liberman, S., Fiore, J. F., Andalib, A., & Lee, L. (2026) · Journal of Surgical Research · doi:10.1016/j.jss.2026.07.051
Transition from preclinical obesity to clinical obesity among US adults: incidences and risk factors
Yao, Z., Dardari, Z., Zahid, S., Silver, N., Razavi, A. C., Erhabor, J., Jelwan, Y. A., Burka, S., & Blaha, M. J. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02199-9
Canal, F. D., Martinelli, C. D. P., Potoczna, N., Wiegand, N., Peros, G., Gantert, W. A., Lazaridis, I. I., Sidler, M., & Delko, T. (2026) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2026.102560
Olaniyi, A. O., Gogineni, K. K., Olaniyi, H., Sabir, H., Eboigbe, G. A., Yerima, S. R., & Gabriels, N. (2026) · Cureus · doi:10.7759/cureus.114962 · Cited by 1
Montoye, A. H. K., Grosicki, G. J., Babcock, M. C., Fielding, F., von Hippel, W., Chapman, C. J., Henderson, D., Lee, V. H., & Holmes, K. E. (2026) · Journal of Sports Sciences · doi:10.1080/02640414.2026.2721858 · Cited by 1
Mallardo, M., Messina, A., Monda, V., Marra, M. L., Monda, A., Allocca, S., Casillo, M., Maio, G. D., Perrone, P., Daniele, A., et al. (2026) · Nutrients · doi:10.3390/nu18172748 · Cited by 1
Kuryłowicz, A., & Czupryniak, L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71226 · Cited by 3
Zhao, Z., & Hu, X. (2026) · Biomedicines · doi:10.3390/biomedicines14091884
Yu, X., Wang, S., Lin, K., & Guan, J. (2026) · European Spine Journal · doi:10.1007/s00586-026-10293-9
Biswas, S., Rani, F., Bhardwaj, K., Bera, C., & Yadav, S. (2026) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20262889
Corrado, R., Raffa, S. D., Bauer, E. M., Eisenberg, D., Weare-Regales, N., Antonovich, N., Loblack, A., Berdiel, E., Kelber, M. S., Klimovich, J., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-00676
Sorić, T., Sarić, A., Ivanišin, A., Lovrić, M., Milić, M., Matovinović, M., & Sarić, M. M. (2026) · Nutrients · doi:10.3390/nu18172757 · Cited by 2
Şahin, F., Karamzad, N., Aletaha, R., Tahmasbi, F., Amiri, F., Sullman, M. J. M., Grieger, J. A., & Safiri, S. (2026) · Adipocyte · doi:10.1080/21623945.2026.2716431
Obesity and Cardiovascular Diseases: CVIA State-of-the-Art Review
Liu, N., Pan, Y., Liu, F., Mei, J., Zhang, X., Zhang, R., Zhang, S., Luo, F., Wu, Y., Gong, Y., et al. (2026) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2026.0010 · Cited by 1
Self-citationMetabolic dysfunction–associated steatotic liver disease
Casler, K., & Chaney, A. J. (2026) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000471
Gopakumar, H., Thompson, C. C., & Jirapinyo, P. (2026) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2026.08.025
Upadhyay, N., Bonakdar, A., Subedi, K., Banerjee, S., Behrend, B., & Hankosky, E. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71250
Prieto, M. S., Romero-Dominguez, M., Orozco, R., Lilue, M., Lubián-López, D. M., González, S. P., Nieto, A., Coronado, P., Sánchez‐Borrego, R., Cano, A., et al. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109101
L’integrazione tra dieta e farmaci nell’era delle nuove terapie per l’obesità
Vitacolonna, E., Masi, D., & Watanabe, M. (2026) · L Endocrinologo · doi:10.1007/s40619-026-01855-6
Yuce, T. K., Radwan, R. M., Lee, Y. A., Holler, E., Dai, H., He, X., Huang, Y., Guo, Y., Bian, J., & Guo, J. (2026) · Obesity · doi:10.1002/oby.70280
Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception
Koca, N., Uyar, S., Şahintürk, Y., Yıldız, H., Prato, S. D., & DeFronzo, R. A. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03346-2
Monteiro, M. P., Frutuoso, J. F., Pereira, S. S., Guimarães, M., & Monteiro, M. P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1870008
Chen, D., Ma, B., Sun, H., Zhang, J., Gong, L., Wang, W., Liu, Z., Zha, H., Du, S., Chen, M., et al. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2026-003026 · Cited by 1
Gilardini, L., Vincenti, V., Croci, M., Martinelli, S., Pasqualinotto, L., Toja, P. M., Cavaggioni, L., & Bertoli, S. (2026) · Journal of Obesity · doi:10.1155/jobe/1224246
Talay, L., Xu, C., Hom, J., Swinckels, L., Tan, M. J., Alderete, J. D., & Ahuja, N. K. (2026) · Medicina · doi:10.3390/medicina62091647
Ahad, A., Hullon, D., Akhavan, M., & Oskouyan, Z. (2026) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-026-10839-8 · Cited by 1
Menopause as a Metabolic Turning Point: Endocrine Mechanisms Linking Hormonal Transition and Obesity
Yanachkova, V. E. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1017242
Burak, M., Harney, K., Sinha, Y., Rawashdeh, A., & Wiggins, T. (2026) · Surgery (Oxford) · doi:10.1016/j.mpsur.2026.07.014
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.